Plus Therapeutics, Inc. (PSTV)
| Market Cap | 26.36M +64.8% |
| Revenue (ttm) | 5.18M -0.5% |
| Net Income | -11.93M |
| EPS | -2.62 |
| Shares Out | 6.88M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 67,553 |
| Open | 3.810 |
| Previous Close | 3.780 |
| Day's Range | 3.810 - 4.000 |
| 52-Week Range | 2.900 - 23.425 |
| Beta | 1.40 |
| Analysts | Strong Buy |
| Price Target | 36.00 (+839.95%) |
| Earnings Date | Aug 13, 2026 |
About PSTV
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company’s lead radiotherapeutic candidate is rhenium obisbemeda, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere to treat various solid organ cancers, such as primary and sec... [Read more]
Financial Performance
In 2025, Plus Therapeutics's revenue was $5.21 million, a decrease of -10.49% compared to the previous year's $5.82 million. Losses were -$22.39 million, 72.5% more than in 2024.
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for PSTV stock is "Strong Buy." The 12-month stock price target is $36.0, which is an increase of 839.95% from the latest price.
News
Plus Therapeutics Secures Regional Coverage Agreement with Medical Mutual for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer
HOUSTON, July 21, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), announced today that it has signe...
Plus Therapeutics, Genomic Testing Cooperative partner on sequencing technology
Plus Therapeutics (PSTV) and Genomic Testing Cooperative announced a collaboration to integrate GTC’s next-generation sequencing technology into the CNSide cerebrospinal fluid assay platform. The coll...
Plus Therapeutics and Genomic Testing Cooperative Partner to Integrate Next-Generation Sequencing Into the CNSide® CSF Assay Platform
Collaboration expected to deliver hundreds of DNA and RNA biomarkers from a single CSF specimen — directly aligned with the updated NCCN Guidelines® (Version 2.2026), which now recognize CSF circulati...
Plus Therapeutics reports NCCN Central Nervous System Cancers guidelines update
Plus Therapeutics (PSTV) highlighted the recent update to the National Comprehensive Cancer Network, or NCCN, Clinical Practice Guidelines in Oncology for Central Nervous System Cancers, including gui...
Plus Therapeutics Highlights NCCN CNS Cancers Guidelines Update and Reinforces Clinical Role of CNSide® in Leptomeningeal Metastases Monitoring
Updated NCCN language continues to support CSF analysis in the diagnosis and management of leptomeningeal metastases, including CSF cytology follow-up every 4 to 8 weeks for patients receiving intrath...
Plus Therapeutics Transcript: Investor update
Rebranding to Cerenome reflects a broader CNS oncology focus, integrating therapeutics, diagnostics, and AI-driven data. REYOBIQ and CNSide platforms are advancing on all 2026 objectives, with payer coverage, clinical trial progress, and AI initiatives on track to drive operational efficiency and growth.
Plus Therapeutics Press release: Investor update
Plus Therapeutics issued a press release on June 30, 2026, disclosing material business information to investors.
Plus Therapeutics to change name, ticker symbol
Plus Therapeutics (PSTV) provided a business update. Notably, the company announces it is changing its company name from Plus Therapeutics to Cerenome and Nasdaq ticker to (CNSY), effective August 3.
Plus Therapeutics Provides Mid-Year Business Update Including Corporate Rebranding
Plus Therapeutics to become Cerenome, to trade under new Nasdaq ticker CNSY on August 3, 2026 Affirms 2026 guidance on key milestones Reports positive CNSide® commercial progress HOUSTON, June 30, 202...
Plus Therapeutics Secures National Coverage Agreement with Elevance Health for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer
HOUSTON, June 25, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), announced today that it has signed a ...
Plus Therapeutics to Provide Business Update Call on June 30, 2026
Management to update on 2026 mid-year progress, milestones and provide details on its integrated CNS oncology strategy and artificial intelligence plans Management to update on 2026 mid-year progress,...
Plus Therapeutics Registration statement: Registration filing
Plus Therapeutics filed a registration statement on June 5, 2026, providing details about a securities offering with the SEC.
Plus Therapeutics Announces CAP Accreditation of CNSide® Diagnostics Clinical Laboratory
HOUSTON, June 04, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a healthcare company advancing precis...
Plus Therapeutics Registration statement: Registration filing
Plus Therapeutics filed a registration statement on June 2, 2026, providing details about a securities offering with the SEC.
Plus Therapeutics files $100M mixed securities shelf
06:08 EDT Plus Therapeutics (PSTV) files $100M mixed securities shelf
Plus announces presentation of health economics study on CNSide CSF assay
Plus Therapeutics (PSTV) announced the presentation of a new health economics study evaluating the economic impact of earlier detection and therapeutic management of LM using the CNSide cerebrospinal ...
Plus' CNSide Diagnostic Platform Demonstrates Substantial Healthcare Cost Reduction in Patients with Leptomeningeal Metastases
Plus and Harvard analysis shows CNSide enables early diagnosis and better clinical decision-making reducing healthcare costs by 40%
Plus Therapeutics enters pact with Ephemeral for AI execution platform
Plus Therapeutics (PSTV) announced that it has signed an agreement to enter into a strategic partnership with Ephemeral Technologies to deliver an AI execution platform for CNS oncology. The AI…
Plus Therapeutics Partners with Ephemeral Technologies to Deploy AI Execution Platform for CNS Oncology
Partnership to deliver a novel AI-native integrated CNS oncology platform Platform will unify and analyze Plus' proprietary therapeutic, diagnostic, and bioinformatics datasets to accelerate precision...
Plus Therapeutics reports Q1 EPS ($1.05), consensus (87c)
Reports Q1 revenue $1.03M, consensus $974,000. “Our team remains focused on our two highest-priority 2026 goals, CNSide commercial scale-up and REYOBIQ pivotal-trial readiness,” said Marc Hedrick, Plu...
Plus Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update on REYOBIQ™ Clinical Program and CNSide® Commercial Rollout
HOUSTON, May 15, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) ("Plus" or the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceu...
Plus Therapeutics Earnings release: Q1 2026
Plus Therapeutics released its Q1 2026 earnings on May 15, 2026, summarizing the period's financial results.
Plus Therapeutics Quarterly report: Q1 2026
Plus Therapeutics has published its Q1 2026 quarterly earnings report on May 15, 2026.
Plus Therapeutics Transcript: AGM 2026
The meeting covered board elections, auditor ratification, executive compensation, and a stock plan amendment, all of which were approved. Voting procedures were clarified, and a reverse stock split was noted as recently effective.
Plus Therapeutics Announces Oral Presentation Highlighting REYOBIQ™ Clinical and Translational Data Demonstrating Favorable Safety, Survival, and Emerging Immunomodulation in Leptomeningeal Metastases
Plenary session at AANS underscores REYOBIQ's potential as a differentiated targeted radiotherapeutic platform for CNS cancers Plenary session at AANS underscores REYOBIQ's potential as a differentiat...